Navegando por Palavras-chave "Lesão pulmonar"

Agora exibindo 1 - 3 de 3
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Clinical significance in non-cystic fibrosis bronchiectasis followed in a real practice
    (Pontifícia Universidade Católica do Paraná, 2013-12-01) Faria Júnior, Newton Santos De; Bigatão, Amilcar Marcelo [UNIFESP]; Santos, Sérgio Ricardo [UNIFESP]; Leitão Filho, Fernando Sérgio Studart; Jardim, José Roberto [UNIFESP]; Oliveira, Luis Vicente Franco; Universidade Nove de Julho; Universidade Federal de São Paulo (UNIFESP); University of Fortaleza Medicine School
    INTRODUCTION: Bronchiectasis is a chronic disorder characterized by permanent dilation of the bronchi and bronchioles accompanied by inflammatory changes in the walls of these structures and adjacent lung parenchyma. OBJECTIVE: The aim of the present study was to perform a clinical and functional characterization of adult patients with non-cystic fibrosis bronchiectasis. METHODS: A clinical, descriptive, retrospective, case-series study was carried out involving 232 patients with non-cystic fibrosis bronchiectasis treated at a lung ambulatory between 2004 and 2012. RESULTS: The sample consisted of 232 patients (134 females; mean age: 52.9 years ± 17.7; body mass index: 23.5 kg/m² ± 4.4). The predominant symptoms were cough (91.4%), expectoration (85.8%) and dyspnea (76.3%). The majority of cases were of a non-tuberculosis etiology (64.7%). Regarding lung function, the obstructive breathing pattern was predominant (43.5%). The most common comorbidities were of a cardiovascular origin (51.0%). CONCLUSIONS: Adult patients with non-cystic fibrosis bronchiectasis (mainly post-infection or post-tuberculosis in origin) are characterized by a low educational level, excessive cough, sputum, dyspnea, muscle fatigue, an obstructive breathing pattern with frequent hypoxemia and multiple comorbidities, mainly of a cardiovascular origin. However, our patients have a low index of exacerbations and hospitalizations that can be assigned to a clinical protocol for monitoring.
  • Imagem de Miniatura
    Item
    Restrito
    Desvantagem vocal e qualidade de vida em voz em pacientes com comprometimento pulmonar por Covid-19
    (Universidade Federal de São Paulo, 2023) Bueno, Lourival Mendes [UNIFESP]; Biase, Noemi Grigoletto De [UNIFESP]; Ramos, Hugo Valter Lisboa; http://lattes.cnpq.br/8162031918311112; https://lattes.cnpq.br/3156326658988323; https://lattes.cnpq.br/8252110131576811
    OBJETIVO: Identificar a desvantagem vocal e a qualidade de vida em voz em pacientes que tiveram comprometimento pulmonar por COVID-19, comparar parâmetros pulmonares entre pacientes que tiveram comprometimento pulmonar por COVID-19 e indivíduos do grupo controle, e também correlacionar os parâmetros pulmonares com os questionários de autoavaliação (IDV-10 e QVV). MÉTODOS: Foram selecionados 35 pacientes que tiveram comprometimento pulmonar por COVID-19 e comparados com 35 indivíduos que não foram acometidos por COVID-19. Foram aplicados dois questionários de autoavaliação (índice de desvantagem vocal e o protocolo de qualidade de vida em voz); mensurados o tempo máximo de fonação, a pressão expiratória forçada (PEF) e a pressão inspiratória forçada (PIF) e realizada a videolaringoscopia. RESULTADOS: Houve uma diferença estatisticamente significativa nos scores dos questionários de autoavaliação da voz (IDV-10 e QVV), na pressão expiratória (PEF) e na pressão inspiratória forçada (PIF), entre os pacientes que tiveram comprometimento pulmonar por COVID-19 e os indivíduos do grupo controle. Foi também observado uma correlação entre a PEF/PIF e os scores dos questionários de autoavaliação da voz. CONCLUSÃO: O comprometimento pulmonar por COVID-19 causou um aumento da desvantagem vocal e uma piora na qualidade de vida em voz nos pacientes, além de reduzir a pressão expiratória e inspiratória forçada, quando comparados aos indivíduos do grupo controle.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Efeito da espuma de polidocanol no parênquima pulmonar após administração em veia periférica de ratos
    (Universidade Federal de São Paulo (UNIFESP), 2016-04-29) Silva, Melissa Andreia de Moraes [UNIFESP]; Miranda Junior, Fausto [UNIFESP]; http://lattes.cnpq.br/0032704511396445; http://lattes.cnpq.br/6749209338440036; Universidade Federal de São Paulo (UNIFESP)
    Background: Sclerotherapy has been gaining increased acceptance and popularity as an effective therapy for the treatment of varicose veins. This attention has fed growing interest into the safety and potential complications of this procedure. There is no evidence of pulmonary complications from foam sclerotherapy in humans; however, animal studies have shown possible damage. Objective: The aim of this study is to show the changes in rat pulmonary parenchyma after the injection of 1% polidocanol foam into the peripheral vein using histological analysis of the inflammatory and fibrosis processes. Method: Twenty-four Wistar albino rats were divided into the following four groups: 24 h Polidocanol, 7 day Polidocanol, 28 day Polidocanol, and control. After foam was injected into the lateral saphenous vein, the lungs of the rats were removed for histological analysis. Results: Alveolar edema was observed in only the 24 h group (p <0.005). Vessel thickening was observed in the 7 and 28 day groups (p <0.001). Interstitial fibrosis was found in only the 28 day group (p=0.006). There was no evidence of venous or arterial thrombosis in either group. Conclusions: Polidocanol foam injection into rat peripheral veins causes alveolar edema, vessel thickening and interstitial fibrosis.